ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1158 • ACR Convergence 2023

    Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection

    Maximiliano Diaz Menindez1, Megan Sullivan2, Benjamin Wang3, Andy Abril3, Vikas Majithia2, Ronald Butendieck3, Colleen T. Ball4 and Florentina Berianu2, 1Mayo Clinic, Phoenix, AZ, 2Mayo Clinic Florida, Jacksonville, FL, 3Mayo Clinic, Jacksonville, FL, 4Mayo Clinic Jacksonville, Jacksonville, FL

    Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
  • Abstract Number: 1164 • ACR Convergence 2023

    Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study

    Carina Soto-Fajardo1, Sinthia Solorzano Flores1, Abish Angeles-Acuña1, Fabian Carranza Enriquez1, Rosa-Elena Escobar-Cedillo2, Saul Renan-Leon2, Karina Arias Callejas3, Alejandra Enriquez-Luna2, Graciliano Ramon-Diaz2 and Carlos Pineda2, 1Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 2Instituto Nacional de Rehabilitacion, Mexico City, Mexico, 3Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico

    Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
  • Abstract Number: 1172 • ACR Convergence 2023

    Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

    Hideaki Tsuji1, Fabricio Espinosa-Ortega2, Maryam Dastmalchi2, Ingrid Lundberg2 and Karin Lodin3, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden

    Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
  • Abstract Number: 1165 • ACR Convergence 2023

    Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America

    Jenice Cheah1, Sangmee Bae2, Tiffany De Leon2, Yuna Lee1 and Christina Charles-Schoeman3, 1University of California Los Angeles, Los Angeles, CA, 2UCLA Rheumatology, Los Angeles, CA, 3UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
  • Abstract Number: 1175 • ACR Convergence 2023

    Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis

    Yusra Hasan1, Katharine Ching Chung2, Dana Ascherman3, Siamak Moghadam-Kia4, Chester V. Oddis3 and Rohit Aggarwal3, 1CHI Health Creighton University Medical Center, Omaha, NE, 2University of Pittsburgh Medical Center, Mckeesport, PA, 3University of Pittsburgh, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…
  • Abstract Number: 1178 • ACR Convergence 2023

    Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter

    Srijan Mittal1, Vanshita Batra1, Parikshit Sen2, Saadia Sasha Ali3, Arpit Mago4, Mark Russell5, Eugenia Gkiaouraki6 and Rohit Aggarwal6, 1Maulana Azad Medical College, New Delhi, India, 2Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, 3King's College Hospital, Epsom, United Kingdom, 4Jawaharlal Nehru Medical College, Belgaum, India, 5King's College Hospital, London, United Kingdom, 6University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Myositis is a rare complex autoimmune disease that is less known and poorly understood, with increased effort required for education of practitioners, students, educators,…
  • Abstract Number: 1167 • ACR Convergence 2023

    Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai3 and Moe Tokunaga(Sakamoto)3, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan

    Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
  • Abstract Number: 1168 • ACR Convergence 2023

    Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)

    Sonali Narain1, Can Hu2, Michael Liu1, Himanshu Vashistha1, Kourosh Shargani3 and Galina Marder1, 1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY

    Background/Purpose: ILD is a major cause of morbidity and mortality in IIM. The diagnosis and progression of ILD often relies on high resolution computed tomography…
  • Abstract Number: 1180 • ACR Convergence 2023

    Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality

    Xinlei Liu1, Fumin Qi2, Wei Wei1 and Yin Zhao1, 1Tianjin Medical University General Hospital, Tianjin, China, 2Tianjin Medical University, Tianjin, China

    Background/Purpose: We describe a single-center clinical cohort of MDA5 positive dermatomyositis(DM) in China and apply a machine learning approach to predict the risk of mortality…
  • Abstract Number: 1163 • ACR Convergence 2023

    Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort

    Sai Koyoda1, Dawn Wahezi2, Xianhong Xie3, Anand Kumthekar4, Clement Tagoe3 and Bibi Ayesha5, 1Essen Medical Center, Rahway, NJ, 2Children's Hospital at Montefiore, New Rochelle, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 5Montefiore Medical Center, Bronx, NY

    Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
  • Abstract Number: 1130 • ACR Convergence 2023

    Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI

    Esperanza Pato1, Lara Borrego-Sanz2, Marta Domínguez3, Fernando Alonso4, Fayna Rodríguez-Gonazález5, Marta Tejera-Santana5, María del Mar Esteban-Ortega6, Isabel García-Lozano7, Lucia Martinez-Costa8, Samuel Gonzalez-Ocampo8, Maite Sainz de la Maza9, Aina Moll-Udina9, Zulema Plaza10, Alejandro Fonollosa-Calduch11, Joseba Artaraz11, Teresa Díaz-Valle12, María Gurrea-Almela12, David Diaz-Valle13 and Rosalía Méndez-Fernández13, 1Hospital Clínico San Carlos, Rheumatology, Madrid, Spain, 2Hospital Clinico San Carlos, Ophthalmology, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4Spanish Society of Rheumatology, Madrid, Spain, 5Hospital Doctor Negrín, Ophthalmology, Gran Canaria, Spain, 6Hospital Infanta Sofia, Madrid, Spain, 7Hospital Infanta Sofia, Ophthalmology, Madrid, Spain, 8Hospital Doctor Peset, Ophthalmology, Valencia, Spain, 9Hospital Clinic of Barcelona, Ophthalmology, Barcelona, Spain, 10Universidad Autónoma de Madrid, Madrid, Spain, 11Hospital de Cruces, Ophthalmology, Bilbao, Spain, 12Hospital De Móstoles, Ophthalmology, Madrid, Spain, 13Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: Standardized and validated outcome measures of disease activity are lacking in the treatment and assessment of uveitis, making it difficult to compare efficacy and…
  • Abstract Number: 1154 • ACR Convergence 2023

    Clinical Presentation of IgG4-Related Disease. Single Referral Hospital Experience and Literature Review

    Fernando López1, Javier Loricera2 and Ricardo Blanco3, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: IgG4-related disease (IgG4-RD) is an inflammatory and fibrosing entity with very heterogeneous clinical manifestations. It was recognized as a new disease entity only 12…
  • Abstract Number: 1147 • ACR Convergence 2023

    Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

    Helena Port I Linares1, Birte Coppers2, Sara Bayat2, Godonou Elie-Tino2, Larissa Valor-Mendez2, David Simon2, Filippo Fagni2, Giulia Corte2, Anne-Christine Bay-Jensen3, Koray Tascilar2, Axel Hueber4, Verena Schoenau2, Michael Sticherling5, Simon Heinrich6, Daniela Bohr2, Georg Schett7, Arnd Kleyer8, Sigrid Leyendecker6, Signe Holm Nielsen3 and Anna-Maria Liphardt9, 1Nordic Bioscience A/S / University of Copenhagen, Copenhagen, Denmark, 2Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 3Nordic Bioscience, Herlev, Denmark, 4Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany, 5Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, 6Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany, 9Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…
  • Abstract Number: 1036 • ACR Convergence 2023

    The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study

    Alojzija Hocevar1, PIERLUIGI MACCHIONI2, Irene Monjo3, Rositsa Karalilova4, Edoardo Conticini5, Alessandro Tomelleri6, Cristina Ponte7, Sara Monti8, Giulia Klinowski9, Zguro Batalov4, Paolo Falsetti10, Corrado Campochiaro11 and Eugenio De Miguel3, 1Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Hospital Universitario La Paz, Madrid, Spain, 4Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 5Tallaght University Hospital, Dublin, Ireland, 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 7Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 8Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 9IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 10San Raffaele Scientific Institute, Siena, Italy, 11IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy

    Background/Purpose: Musculoskeletal ultrasound (US) is a validated method for the objective assessment of the pathological changes occurring in PMR. It assists the diagnosis of the…
  • Abstract Number: 1031 • ACR Convergence 2023

    Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System

    Joseph Kim1, Song Zhang2 and Elizabeth Blair Solow1, 1UT Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality, particularly if RA is poorly controlled. The effects of socioeconomic deprivation have not been…
  • « Previous Page
  • 1
  • …
  • 242
  • 243
  • 244
  • 245
  • 246
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology